Business Wire

WA-SPIE

30.9.2021 11:05:11 CEST | Business Wire | Press release

Share
SPIE and the University of Birmingham Establish $800,000 Photonics-focused Education Fund

SPIE, the international society for optics and photonics , and the University of Birmingham have announced the establishment of the SPIE Optics and Photonics Champion Academy fund. The new endowment was announced this morning, during SPIE Photonex + Vacuum Technologies in Glasgow, Scotland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005066/en/

The $400,000 gift from the SPIE Endowment Matching Program will be matched 100% by the university, and the $800,000 fund will create and support the SPIE Optics and Photonics Champion Academy. The cohort-focused program will engage in areas of public interest in the fields of quantum technology and biomedical imaging and data sciences: one of the first projects will address pandemics. The program will be led by Professor and Principal Investigator of the UK Quantum Technology Hub Sensors and Timing Kai Bongs , and Professor of Computational Life Sciences Iain Styles .

The SPIE Optics and Photonics Champion Academy will support University of Birmingham students in a variety of ways which include expanding cross-disciplinary educational opportunities in optics and photonics; offering students hands-on support and training to become influential science communicators and advocates of optics and photonics; and by utilizing a range of stipends, awards, and activity grants, which will be supplemented with professional development and mentoring opportunities from the university’s academic leaders as well as from external experts.

The program will focus particularly on students in underrepresented groups, early-career researchers, and PhD students in order to establish and build a broad, diverse, and inclusive network of science advocates, especially in the area of optics and photonics.

“We are delighted to be able to work with SPIE to launch this unique Academy at the University of Birmingham,” said Professor Bongs. “This initiative will help to accelerate the growth of optics and photonics expertise, which will have great impact far beyond the university. Our hope is to not only encourage this learning, but to also create awareness of the huge importance of this subject area in tackling real-world problems.”

“By equipping early-career optics and photonics researchers and PhD students with skills in advanced data analysis, we will help to accelerate the translation of these exciting technologies from the laboratory to their adoption in real-world applications,” added Professor Styles. “Our SPIE Champions will be able to work with experts in diverse application areas such as healthcare and climate monitoring to develop end-to-end optics-based solutions with integrated analytics for some of our most pressing challenges.”

“By offering direct, experiential training in quantum technology and biomedical imaging as well as highlighting various career options in the field, the SPIE Optics and Photonics Champion Academy will develop a natural pipeline of future professional scientists and engineers in these fields,” noted SPIE President David Andrews . “And by encouraging students to actively raise awareness of the impact of optics and photonics to their contemporaries, peers, and younger colleagues, the program will be creating visible, engaged role models for future generations.”

The SPIE Endowment Matching Program was established in 2019 to increase international capacity in the teaching and research of optics and photonics, and to date has given more than $3.4 million in matching gifts, resulting in more than $9 million in dedicated funds. The SPIE Endowment Matching Program supports optics and photonics education and the future of the industry by contributing a match of up to $500,000 per award to college and university programs with optics and photonics degrees, or with other disciplines allied to the SPIE mission.

About SPIE

SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye